Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Hyung Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, talks about a new trial investigating a drug targeting HIF-2α, in combination with pembrolizumab, as an adjuvant therapy for patients with kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.